NU · neighbordoorsrecords over spin
Open in NU's Reading Room →

Therapeutic Peptides: What the Records Actually Show (GLP-1 vs. BPC-157)

NU ranks records over spin. This page is not medical advice, and nothing here is a recommendation to take, start, or stop anything. "Therapeutic peptides" is a real, enormous research field — and within it, the evidence ranges from FDA-approved-and-proven all the way down to "interesting in rats, almost untested in humans." The whole point of this page is to keep those two ends from blurring together. Read it, then talk to your doctor.

Start with the scale, because it's real

Peptides — short chains of amino acids your body already uses as signaling molecules — are a legitimate and crowded area of drug development. On EuropePMC, a keyword search for therapeutic peptides returns roughly 364,800 indexed papers (a broad keyword match; the exact-phrase count is far smaller, in the low thousands — the field is large either way). ClinicalTrials.gov lists tens of thousands of studies involving peptides. This is not a fringe corner. Real titles in the literature include "Systemic Pharmacokinetic Principles of Therapeutic Peptides" and "Therapeutic peptides and proteins: Status and developments in drug delivery."

So when someone says "peptides are unproven," that's wrong as a blanket claim. And when someone says "this specific peptide is proven" — that usually needs checking one molecule at a time. The category is huge; the evidence per molecule is wildly uneven.

(Counts below were pulled live from EuropePMC and ClinicalTrials.gov and will drift over time. Search totals depend heavily on exact query wording — treat them as orders of magnitude, not precise figures, and re-run the search yourself if a number matters to you.)

The approved success story: GLP-1 drugs (PROVEN)

The strongest sourced point on this page is also the most boring kind of proof: large randomized human trials and a regulator's signature.

GLP-1 receptor agonists — semaglutide is the famous one — are peptide-based drugs. They are FDA-approved, sold under brand names for type 2 diabetes and for chronic weight management, and they sit on a deep evidence base: EuropePMC shows roughly 15,400 papers mentioning semaglutide, and ClinicalTrials.gov returns on the order of 700+ studies for semaglutide (and several thousand for "GLP-1" more broadly). This is human-trial, PROVEN-level evidence — cardiovascular outcome trials, weight-loss endpoints, the works.

The honest caveats still apply: approved does not mean side-effect-free (GI effects are common, and long-term and rare risks are still being characterized), and approval is for specific uses in specific populations. But the category-level lesson is the one that matters: a peptide can clear the highest bar. GLP-1 is the existence proof.

The grey-market case: BPC-157 (mostly ANIMAL evidence)

BPC-157 is the peptide you've probably seen marketed for tendon, gut, and "healing" — sold as a research chemical, not a medicine. Here the records tell a sharply different story.

Put bluntly: BPC-157 has animal-level support for several effects and near-zero published human-trial support. It is not FDA-approved for any use, and the FDA has placed it on a list of substances that present safety risks for use in compounding. It is largely sold through grey-market channels of varying and unverified purity. That is a very different evidence level from GLP-1, and the gap — hundreds of registered semaglutide trials vs. 2 for BPC-157 — is the whole story.

Why the gap exists (incentives, not conspiracy)

Here's NU's thesis, and it is not "they're hiding a cure." Nobody is hiding anything. The driver is mundane and public: money follows patents.

A novel, patentable molecule like semaglutide can support hundreds of millions of dollars in trial spending because a company can recoup it. An older, hard-to-patent peptide has no comparable sponsor willing to fund the expensive Phase 2/3 human trials that would actually settle whether it works and is safe. So it stays stuck at the animal-and-anecdote stage — not because it's been proven and suppressed, but because the trials that would prove or disprove it are largely unfunded.

That cuts both ways, and honesty requires saying so: "under-studied" does not mean "secretly effective." It means we don't know — and the absence of human data is itself a reason for caution, not a hidden endorsement.

A note on viral claims

If you've seen a specific dramatic statistic about a peptide — a precise healing percentage, a hard recovery-time number, a safety figure — treat it as unverified unless it traces to a registered trial or a peer-reviewed human study you can open. Marketing copy and forum lore routinely launder rat-study effect sizes into human-sounding promises. NU's rule: a number you can't pull from a primary record is a number you flag, not one you repeat.

Safety, plainly

Bottom line

Bring this to your doctor as questions, not conclusions. Don't start or stop any treatment based on this page.

NU original — sourced analysis of the public record. Read it in the interactive Reading Room, or browse more at neighbordoors.com.

Transparency: NU articles are AI-assisted and editor-reviewed, built from the cited primary sources. We label what's proven, alleged, and opinion.